Citius Oncology, Inc. logo

Citius Oncology, Inc.(CTOR)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$7.21
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for CTOR

11/13/2026: CTOR (1-star) is currently NOT-A-BUY. Pass it for now.

Citius Oncology, Inc. is a commercial-stage biopharmaceutical company focused on targeted oncology therapies, anchored by its FDA-approved flagship product LYMPHIR for cutaneous T-cell lymphoma. The company's primary growth story centers on expanding institutional adoption and exploring combination clinical trials to drive revenue scaling. However, it faces execution risks, commercialization hurdles, and ongoing net losses typical of early-stage specialty biotech firms. The stock is best suited for growth-oriented investors with a high risk tolerance willing to monitor quarterly unit shipment metrics and commercial execution progress.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fit while signal remains positiveThe company offers early-stage commercial revenue growth driven by the rollout of its flagship oncology drug LYMPHIR.
Momentum investorStrong fit while signal remains positiveMomentum fit depends on positive technical breakout signals accompanying accelerating quarterly product shipment updates.
Value investorWeak fitCurrent net losses and early-stage profitability profile make it unsuitable for traditional value metrics.
Dividend investorWeak fitThe company does not pay dividends, retaining all capital for commercialization and operational scaling.
Low-risk investorWeak fitHigh clinical, commercial, and price volatility risks are inherent to small-cap biotechnology stocks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighSmall-cap biotechnology shares experience sharp price swings based on commercial updates and market sentiment.
Valuation riskMedium / highValuation relies heavily on future commercial adoption projections rather than current earnings.
Competition risk (targeted oncology and immunotherapy)Medium / highThe company faces competition from established therapies and alternative oncology pipelines.
Business qualityMediumIt features a validated FDA-approved asset but remains early in establishing a diversified commercial portfolio.
Dividend incomeLow / noneNo dividend is paid or anticipated in the near term.
Execution riskHighSuccess depends heavily on effective commercial execution, physician adoption, and scaling institutional orders.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 60.68M USD
Price to earnings Ratio -
1Y Target Price 4
Price to earnings Ratio -
1Y Target Price 4
Volume (30-day avg) 134.4K shares
Beta 3.58
52 Weeks Range 0.49 - 1.83
Updated Date 11/15/2026
52 Weeks Range 0.49 - 1.83
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.48

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Drug Manufacturers - Specialty & Generic

BUY participation
66.7%
Active BUY / eligible
8 / 12
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 205.97%
Avg. Invested days 29
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 4.0
Stock Returns Performance Upturn Returns Performance icon 5.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
CTOR receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
CTOR has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and moderate ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-17.1%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
CTOR's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
CTOR's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-17.1%, negative) and free-cash-flow growth (-4446.7%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 15.1% (soft) and 26.1% of outstanding shares are publicly tradable (soft). Insider ownership of 77.51% supports management-shareholder alignment.

Top 5 Institutional Investors

Armistice Capital, LLC 8.23%
Bank of America Corp 3.63%
Vanguard Capital Management, LLC 0.52%
UBS Group AG 0.32%
Geode Capital Management, LLC 0.23%

Unit Economics (Per $1K Revenue)

★★★★★
CTOR generates approximately $0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -4.46% (Tax Credit)

Quantitative Style Profile

★★★★★
CTOR has a High Volatility Profile profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Commercial Product Sales (United States)Revenues generated from commercial sales of LYMPHIR to U.S. wholesalers and institutional healthcare providers.The company makes money by selling its FDA-approved targeted cancer therapy to hospitals and specialty treatment centers.

Valuation

Trailing PE -
Forward PE 5.82
Enterprise Value 54.33M
Price to Sales(TTM) 8.54
Enterprise Value 54.33M
Price to Sales(TTM) 8.54
Enterprise Value to Revenue 7.65
Enterprise Value to EBITDA -
Shares Outstanding 105.76M
Shares Floating 27.63M
Shares Outstanding 105.76M
Shares Floating 27.63M
Percent Insiders 77.51
Percent Institutions 15.06

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.